Supreme Court Skips Review in Takeda Unit Crohn’s Drug Suit

Takeda Pharmaceutical Co. unit Shire US Inc. failed to convince the US Supreme Court to review a federal appeals court decision that reinstated a golf instructor’s lawsuit over the Crohn’s disease drug Lialda.

Mark Blackburn’s doctor prescribed Lialda in 2013. Blackburn’s advanced stage kidney disease was diagnosed in 2015, and he contended that Shire should have given his doctor more detailed instructions about monitoring patients’ kidney function.

At issue was whether federal law preempts Blackburn’s Georgia law-based claims, which hinges on whether Shire could have altered the label language without approval from the Food and Drug Administration. Conflict preemption principles ...